Cytokine imbalance in systemic lupus erythematosus: A study on northern Indian subjects

Lupus

Volumn 21, Issue 6, 2012, Pages 596-603

  Arora, V ^a   Verma, J ^b   Marwah, V ^c   Kumar, A ^d   Anand, D ^e   Das, N ^e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SIR GANGA RAM HOSPITAL   (India)

^c Command Hospital ^*  (India)

^d FORTIS HOSPITAL   (India)

^e ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

interferon gamma; interleukin 10; interleukin 4; Systemic lupus erythematosus; tumor necrosis factor alpha

Indexed keywords

CYTOKINE; DNA ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; INDIAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INDIA; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; LUPUS ERYTHEMATOSUS, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859909850     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311434937     Document Type: Article

References (73)

1. Silva C, Isenberg DA. Aetiology and pathology of systemic lupus erythematosus. Hospital Pharm. 2001 ; 8: 62-68
2. Kim HA, Chung JW, Park HJ, et al. An antinuclear antibody-negative patient with lupus nephritis. Korean J Intern Med. 2009 ; 24: 76-79
3. Heinlen LD, McClain MT, Ritterhouse LL, et al. 60 kD Ro and nRNP A frequently initiate human lupus autoimmunity. PLoS One. 2010 ; 5: e9599 - e9599
4. Rood MJ, van der Velde EA, Ten Cate R, Breedveld FC, Huizinga TWJ. Female sex hormones at the onset of systemic lupus erythematosus affect survival. Br J Rheumatol. 1998 ; 37: 1008-1010
5. Lee H, Sugino H, Nishimoto N. Cytokine networks in systemic lupus erythematosus. J Biomed Biotechnol. 2010 ; 2010: 676284-676288
6. Sekigawa I, Fujishiro M, Yamaguchi A, et al. A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus. Clin Exp Rheumatol. 2010 ; 28: 419-423
7. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis. 2000 ; 59: 243-251
8. Kumar A. Indian guidelines on the management of SLE. J Indian Rheumatol Assoc. 2002 ; 10: 80-96
9. Malaviya AN, Chandrasekaran AN, Kumar A, Shamar PN. Systemic lupus erythematosus in India. Lupus. 1997 ; 6: 690-700
10. Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in India. Lupus. 1993 ; 2: 115-118
11. Samanta A, Roy S, Feehally J, Symmons DP. The prevalence of diagnosed systemic lupus erythematosus in whites and Indian Asian immigrants in Leicester City, UK. Br J Rheumatol. 1992 ; 31: 679-682
12. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis. 1955 ; 1: 12-32
13. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995 ; 22: 1259-1264
14. Peschken CA, Esdaile JM. Systemic lupus erythematosus in North American Indians: a population based study. J Rheumatol. 2000 ; 27: 1884-1891
15. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol. 2000 ; 27: 685-691
16. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 ; 82: 299-308
17. Mok CC, Mak A, Chu WP, To CH, Wong SN. Long-term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age-groups. Medicine (Baltimore). 2005 ; 84: 218-224
18. Kumar A, Malaviya AN, Singh RR, Singh YN, Adya CM, Kakkar R. Survival in patients with systemic lupus erythematosus in India. Rheumatol Int. 1992 ; 12: 107-109
19. Murali R, Jeyaseelan L, Rajaratnam S, John L, Ganesh A. Systemic lupus erythematosus in Indian patients: prognosis, survival and life expectancy. Natl Med J India. 1997 ; 10: 159-164
20. Patel M, Clarke AM, Bruce IN, Symmons D. The prevalence and incidence of biopsy-proven lupus nephritis in the UK. Arthritis Rheum. 2006 ; 54: 2963-2969
21. Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol. 1998 ; 17: 110-114
22. Chang DM, Su WL, Chu SJ. The expression and significance of intracellular T helper cytokines in systemic lupus erythematosus. Immunol Invest. 2002 ; 31: 1-12
23. Antiga E, Del Bianco E, Difonzo E, Fabbri P, Caproni M. Serum levels of the regulatory cytokines transforming growth factor-β and interleukin-10 are reduced in patients with discoid lupus erythematosus. Lupus. 2011 ; 20: 556-560
24. Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR. The role of IFN-g in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 2001 ; 3: 136-141
25. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004 ; 13: 339-343
26. Blenman KR, Duan B, Xu Z, et al. IL-10 regulation of lupus in the NZM2410 murine model. Lab Invest. 2006 ; 86: 1136-1148
27. Arora V, Mondal AM, Grover R, Kumar A, Chattopadhyay P, Das N. Modulation of CR1 transcript in systemic lupus erythematosus (SLE) by IFN-g and immune complex. Mol Immunol. 2007 ; 44: 1733-1739
28. Kidd P. Th1/Th2 Balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003 ; 8: 223-246
29. Khalifeh MS, Al-Rukibat R, Hananeh W, Boumezrag A, Okour O. Investigation of the role of tumour necrosis factor-{alpha}, interleukin-1{beta}, interleukin-10, nitric oxide and rheumatoid factor-immunoglobulin M in a rat model of arthritis. Lab Anim. 2010 ; 44: 143-149
30. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
31. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
32. Lacki JK, Leszczynski P, Kelemen J, Muller W, Mackiewicz SH. Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J Med. 1997 ; 28: 99-107
33. Viallard JF, Pellegrin JL, Ranchin V. Th1 (IL-2, interferon-gamma (IFN-γ)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999 ; 115: 189-195
34. Gröndal G, Gunnarsson I, Rönnelid J, Rogberg S, Klareskog L, Lundberg . Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000 ; 18: 565-570
35. Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007 ; 27: 461-466
36. Lee T, Leu SJ, Huang CJ, et al. Anti-ribosomal phosphoprotein autoantibody triggers interleukin-10 overproduction via phosphatidylinositol 3-kinase-dependent signalling pathways in lipopolysaccharide-activated macrophages. Immunology. 2009 ; 127: 91-102
37. Jacobs R, Pawlak CR, Mikeska E, et al. Systemic lupus erythematosus and rheumatoid arthritis patients differ from healthy controls in their cytokine pattern after stress exposure. Rheumatology. 2001 ; 40: 868-875
38. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991 ; 174: 1209-1220
39. Bogdan C, Vodovotz Y, Nathan C. Macrophage deactivation by interleukin 10. J Exp Med. 1991 ; 174: 1549-1555
40. Gazzinelli RT, Oswald IP, James SL, Sher A. IL-10 inhibits parasite killing and nitrogen oxide production by IFN-gamma-activated macrophages. J Immunol. 1992 ; 148: 1792-1796
41. Silva JS, Morrissey PJ, Grabstein KH, Mohler KM, Anderson D, Reed SG. Interleukin 10 and interferon gamma regulation of experimental Trypanosoma cruzi infection. J Exp Med. 1992 ; 175: 169-174
42. de Waal Malefyt R, Figdor CG, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol. 1993 ; 151: 6370-6381
43. Delves P, Roitt I Encyclopedia of immunology. 2 nd edn. San Diego: Academic Press, 1998, p. 103. San Diego: Academic Press ; 1998, p. 103 :
44. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med. 1994 ; 179: 305-310
45. Yap DY, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol. 2010 ;: 365083-365093
46. Llorente L, Zou W, Levy Y, et al. Role of Interleukin-10 in the B-lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 1995 ; 181: 839-844
47. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 1998 ; 16: 283-288
48. El-Sayed M, Nofal E, al Mokadem S, al Makhzangy I, Gaballah H, Akl H. Correlative study of serum Th1/Th2 cytokines levels in patients with systemic lupus erythematosus with SLEDAI. Egypt Dermatol Online J. 2008 ; 4: 3-19
49. Sabat R, Grütz G, Warszawska K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010 ; 21: 331-344
50. Lee SW, Hong YS, Chun CM, et al. Anti-inflammatory effects of IL-4 and IL-10 on human polymorphonuclear leukocytes. J Korean Med Sci. 2002 ; 17: 7-14
51. Calvani N, Richards HB, Tucci M, Pannarale G, Silvestris F. Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis. Clin Exp Immunol. 2004 ; 138: 171-178
52. Gómez D, Correa PA, Gómez LM, Cadena J, Molina JF, Anaya JM. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?. Semin Arthritis Rheum. 2004 ; 33: 404-413
53. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol. 1987 ; 70: 562-569
54. Al-Janadi M, Al-Balla S, Al-Dalaan A, Raziuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases. J Clin Immunol. 1993 ; 13: 58-67
55. Tokano Y, Morimoto S, Kaneko H, et al. Levels of IL-12 in the sera of patients with systemic lupus erythematosus (SLE)-relation to Th1- and Th2-derived cytokines. Clin Exp Immunol. 1999 ; 116: 169-173
56. Robak E, Smolewski P, Wozniacka A, Sysa-Jedrzejowska A, Stepien H, Robak T. Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus. Eur Cytokine Netw. 2004 ; 15: 222-230
57. Moore KW, de Waal Malefyt R, Coffman RL, O Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001 ; 19: 683-765
58. Emilie D, Llorente L, Galanaud P. Cytokines and systemic lupus erythematosus. Ann Med Intern. 1996 ; 147: 480-484
59. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol. 1999 ; 18: 17-22
60. Mahmoudn RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem. 2005 ; 38: 134-141
61. Sabry A, Sheashaa H, El-Husseini A, et al. Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine. 2006 ; 35: 148-153
62. Swadzba J, Iwaniec T, Musial J. Increased level of tumor necrosis factor-alpha in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state. Rheumatol Int. 2011 ; 31: 307-313
63. Keystone EC, Ware CF. Tumor necrosis factor and anti-tumor necrosis factor therapies. J Rheumatol Suppl. 2010 ; 85: 27-39
64. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem. 1985 ; 260: 2345-2354
65. Oppenheim JJ, Neta R. Pathophysiological roles of cytokines in development, immunity, and inflammation. FASEB J. 1994 ; 8: 158-162
66. Aringer M, Smolen JS. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthritis Res Ther. 2008 ; 10: 202-210
67. Tucci M, Lombardi L, Richards HB, Dammacco F, Silvestris F. Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis. Clin Exp Immunol. 2008 ; 154: 247-254
68. Lourenço EV, La Cava A. Cytokines in systemic lupus erythematosus. Curr Mol Med. 2009 ; 9: 242-254
69. Kassi E, Moutsatsou P. Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2010 ;: 317452-317464
70. Apostolidis SA, Lieberman LA, Kis-Toth K, Crispín JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res (in press).
71. Akahoshi M, Nakashima H, Tanaka H, et al. th1/th2 balance of peripheral t helper cells in systemic lupus erythematosus. Arthritis Rheum. 1999 ; 42: 1644-1648
72. Llorente L, Richard Patin Y, Fior R, et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome and systemic lupus erythematosus. A potential mechanism of B cell hyperactivity and autoimmunity. Arthritis Rheum. 1994 ; 37: 1647-1655
73. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005 ; 2005: 273-279